Privium Fund Management’s Fate Therapeutics FATE Stock Holding History

Privium Fund Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$982K	Hold	414,311	–	–	0.19%	40
2026 Q2	$1.12M	Hold	414,311	–	–	0.21%	44
2026 Q1	$497K	Buy	414,311 +45,211	+12%	+$55K	0.1%	54
2025 Q4	$363K	Buy	369,100 +35,881	+11%	+$43.1K	0.07%	52
2025 Q3	$420K	Buy	333,219 +222,129	+200%	+$239K	0.08%	53
2025 Q2	$127K	Buy	111,090 +2,064	+2%	+$2.4K	0.03%	54
2025 Q1	$86.1K	Buy	109,026 +22,026	+25%	+$27K	0.02%	55
2024 Q4	$144K	Buy	87,000 +37,000	+74%	+$93.2K	0.03%	61
2024 Q3	$175K	Buy	+50,000	New	+$195K	0.04%	76

Other funds holding FATE

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Parametrica Management Wanchai, Hong Kong $142M AUM 113.92% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return

Privium Fund Management's FATE Position: Q3 2026 in Review

Privium Fund Management held its Fate Therapeutics (FATE) position steady in Q3 2026 at 414,311 shares worth $982K. The position accounts for 0.19% of the portfolio, ranked #40.

Privium Fund Management first reported a position in FATE in Q3 2024 and has held it in 9 quarters since. The position peaked at $1.12M in Q2 2026. 29 funds tracked by Wall St. Rank hold FATE as of Q3 2026.

Privium Fund Management held 414,311 shares of Fate Therapeutics worth $982K as of Q3 2026.
Privium Fund Management left its Fate Therapeutics share count unchanged in Q3 2026.
Fate Therapeutics made up 0.19% of Privium Fund Management's portfolio in Q3 2026, its #40 holding.
Privium Fund Management first reported a position in Fate Therapeutics in Q3 2024 and has held it in 9 quarters since.
Privium Fund Management's Fate Therapeutics position peaked at $1.12M in Q2 2026.
29 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2026.

Based on Privium Fund Management's 13F filing for Q3 2026, filed 3 Nov 2026.